GlassScriptPhysician profile
Richard David Fish
NPI 1487608352
$8,579.71
in general payments reported to CMS, 2019-2025
46 companies · $643 in 2025
The $643 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,857 · 2020: $412 · 2021: $1,223 · 2022: $1,764 · 2023: $1,259 · 2024: $1,421 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,183.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $925.40 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $697.72 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $688.69 | 2021-2025 | Wegovy, Ozempic, Fiasp |
| Amgen INC. | $558.28 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $420.83 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $379.49 | 2020-2025 | |
| Abbott Laboratories | $359.29 | 2019-2024 | Xience Skypoint, Cardiomems |
| Kowa Pharmaceuticals America, INC. | $287.58 | 2019-2023 | Livalo |
| Impulse Dynamics (USA) INC. | $274.55 | 2021-2024 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $246.83 | 2019-2024 | |
| Boston Scientific Corporation | $240.35 | 2019-2024 | Ranger, Lux-Dx Insertable Cardiac Monitor |
| Shockwave Medical, INC | $187.91 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amarin Pharma, INC. | $179.06 | 2019-2022 | |
| Medtronic, INC. | $164.32 | 2021-2024 | Endurant Iis, Corevalve Evolut R |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.